Investor Alert: Pomerantz Law Firm Launches Investigation into Adverum Biotechnologies Claims

Pomerantz LLP, a well-established law firm known for its focus on corporate and securities class action litigation, is currently investigating potential claims on behalf of investors associated with Adverum Biotechnologies, Inc. (NASDAQ: ADVM). The firm is reaching out to individuals who have engaged with the company during significant periods, especially regarding their investment decisions.

Context of the Investigation

The inquiry addresses concerns that Adverum and its executives may have been involved in securities fraud or engaged in dubious business practices. This investigation has come to light following a June 31, 2025, filing to the U.S. Securities and Exchange Commission (SEC). In this disclosure, the company alerted stakeholders that several of its previously issued financial statements could no longer be trusted due to inaccuracies identified in the accounting for tenant improvement allowances associated with an operating lease and sublease connected to a property in North Carolina, referred to as the 'NC Premises'.

Financial Ramifications

Adverum's announcement regarding the inaccuracies led to a considerable decline in its stock price. Within a day of the news, shares fell by $0.54, equating to a 12.36% drop, resulting in a closing price of $3.83 per share on April 1, 2025. This sharp decrease reflects investor concerns and highlights the potential significance of the findings that prompted the legal investigation.

Role of Pomerantz LLP

Pomerantz LLP has cultivated a strong reputation as a leading firm in securities class actions, with deep roots tracing back to its founder, Abraham L. Pomerantz, often recognized as the dean of the class action bar. With a significant history spanning over 85 years, the firm remains committed to advocating for victims of securities fraud and focuses on recovering substantial awards for its clients affected by corporate misconduct.

Contact Information

Investors impacted by the recent developments regarding Adverum are encouraged to reach out to Danielle Peyton at Pomerantz LLP for guidance. She can be contacted via email at [email protected] or directly at 646-581-9980, extension 7980.

This investigation underscores the ongoing scrutiny faced by companies in the biotechnology sector and the critical importance of transparent financial reporting. Investors are urged to stay informed and proactive, especially in light of potential legal ramifications stemming from corporate disclosures.

For anyone who may be interested in joining the related class action lawsuit, additional information is available through the Pomerantz firm's resources.

In conclusion, as the landscape of investor relations and corporate governance continues to evolve, this case serves as a reminder of the need for vigilance within the investment community. Stakeholders are advised to keep abreast of developments that could impact their investments and to consider the implications of corporate transparency and accountability.